Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready To Meet Demand?
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ramp up production enough. Source link
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal By Reuters
By Foo Yun Chee and Maggie Fick BRUSSELS/LONDON (Reuters) – EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings’ planned $16.5 billion takeover of Catalent (NYSE:), people familiar with the matter said. Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk (NYSE:), whose profits from blockbuster weight-loss drug Wegovy propelled it to become Europe’s most valuable company
Recent News
-
-
-
El Salvador Is Getting Its First Tokenized U.S. Treasuries Offering
November 20, 2024 -
Super Micro Options Imply More Volatility for the Stock
November 20, 2024 -
MSF charity halts work in Port-au-Prince over attacks
November 20, 2024 -
Mike Tyson, Jake Paul fight was most-streamed sports event: Netflix
November 20, 2024 -
-
-
-
-
BTC Hits New ATH, GOAT and BONK Rise 8-13%
November 20, 2024 -
-
Kremlin Says Russia-US Hotline to Deflate Crisis Not in Use
November 20, 2024 -
Comcast to spin off NBCUniversal TV networks
November 20, 2024 -
Frontier Airlines is adding 16 new routes. Here’s where they are.
November 20, 2024 -
-
-
-
-
